These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 36470546)

  • 1. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.
    Paolisso P; Bergamaschi L; Gragnano F; Gallinoro E; Cesaro A; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Esposito G; Morici N; Andrea OJ; Casella G; Mauro C; Vassilev D; Galie N; Santulli G; Marfella R; Calabrò P; Pizzi C; Barbato E
    Pharmacol Res; 2023 Jan; 187():106597. PubMed ID: 36470546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.
    Paolisso P; Bergamaschi L; Santulli G; Gallinoro E; Cesaro A; Gragnano F; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Casella G; Mauro C; Vassilev D; Marfella R; Calabrò P; Barbato E; Pizzi C
    Cardiovasc Diabetol; 2022 May; 21(1):77. PubMed ID: 35570280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study.
    Cesaro A; Gragnano F; Paolisso P; Bergamaschi L; Gallinoro E; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Esposito G; Morici N; Oreglia JA; Casella G; Mauro C; Vassilev D; Galie N; Santulli G; Pizzi C; Barbato E; Calabrò P; Marfella R
    Front Cardiovasc Med; 2022; 9():1012220. PubMed ID: 36237914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry.
    Paolisso P; Bergamaschi L; Cesaro A; Gallinoro E; Gragnano F; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Belmonte M; Esposito G; Morici N; Andrea Oreglia J; Casella G; Mauro C; Vassilev D; Galie N; Santulli G; Calabrò P; Barbato E; Marfella R; Pizzi C
    Diabetes Res Clin Pract; 2023 Aug; 202():110766. PubMed ID: 37276980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients.
    Cai D; Chen Q; Mao L; Xiao T; Wang Y; Gu Q; Wang Q; Ji Y; Sun L
    Eur J Clin Pharmacol; 2024 Apr; 80(4):613-620. PubMed ID: 38319348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Early SGLT2 Inhibitors Initiation in Diabetic Patients Following Acute Myocardial Infarction, a Retrospective Study.
    Moady G; Yakubovich I; Atar S
    J Cardiovasc Pharmacol Ther; 2024; 29():10742484241252474. PubMed ID: 38711298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry.
    Ge Z; Baber U; Claessen BE; Farhan S; Chandrasekhar J; Li SX; Sartori S; Kini AS; Rao SV; Weiss S; Henry TD; Vogel B; Sorrentino S; Faggioni M; Kapadia S; Muhlestein B; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):E112-E119. PubMed ID: 30351514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study.
    Bromage DI; Godec TR; Pujades-Rodriguez M; Gonzalez-Izquierdo A; Denaxas S; Hemingway H; Yellon DM
    Cardiovasc Diabetol; 2019 Dec; 18(1):168. PubMed ID: 31815634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation.
    Kwon O; Myong JP; Lee Y; Choi YJ; Yi JE; Seo SM; Jang SW; Kim PJ; Lee JM
    J Am Heart Assoc; 2023 Jul; 12(14):e027824. PubMed ID: 37421263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and Prognostic Impact of Heart Failure Hospitalization During Follow-Up After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction.
    Taniguchi T; Shiomi H; Morimoto T; Watanabe H; Ono K; Shizuta S; Kato T; Saito N; Kaji S; Ando K; Kadota K; Furukawa Y; Nakagawa Y; Horie M; Kimura T
    Am J Cardiol; 2017 Jun; 119(11):1729-1739. PubMed ID: 28407886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis.
    Sardu C; Trotta MC; Sasso FC; Sacra C; Carpinella G; Mauro C; Minicucci F; Calabrò P; D' Amico M; D' Ascenzo F; De Filippo O; Iannaccone M; Pizzi C; Paolisso G; Marfella R
    Cardiovasc Diabetol; 2023 Apr; 22(1):80. PubMed ID: 37005586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes.
    Marfella R; Sardu C; D'Onofrio N; Fumagalli C; Scisciola L; Sasso FC; Siniscalchi M; Marfella LV; D'Andrea D; Minicucci F; Signoriello G; Cesaro A; Trotta MC; Frigé C; Prattichizzo F; Balestrieri ML; Ceriello A; Calabrò P; Mauro C; Del Viscovo L; Paolisso G
    BMC Med; 2023 Feb; 21(1):71. PubMed ID: 36829203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI.
    Kültürsay B; Yılmaz C; Güven B; Mutlu D; Karagöz A
    Kardiol Pol; 2024; 82(1):29-36. PubMed ID: 38230461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy comparison of primary percutaneous coronary intervention by drug-coated balloon angioplasty or drug-eluting stenting in acute myocardial infarction patients with de novo coronary lesions].
    Zhang DP; Wang LF; Liu Y; Li KB; Xu L; Li WM; Ni ZH; Xia K; Zhang ZY; Yang XC
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Jul; 48(7):600-607. PubMed ID: 32842271
    [No Abstract]   [Full Text] [Related]  

  • 15. Sex-specific outcomes of diabetic patients with acute myocardial infarction who have undergone percutaneous coronary intervention: a register linkage study.
    Blöndal M; Ainla T; Marandi T; Baburin A; Eha J
    Cardiovasc Diabetol; 2012 Aug; 11():96. PubMed ID: 22882797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-type natriuretic peptide and risk of contrast-induced acute kidney injury in acute ST-segment-elevation myocardial infarction: a substudy from the HORIZONS-AMI trial.
    Jarai R; Dangas G; Huber K; Xu K; Brodie BR; Witzenbichler B; Metzger DC; Radke PW; Yu J; Claessen BE; Genereux P; Mehran R; Stone GW
    Circ Cardiovasc Interv; 2012 Dec; 5(6):813-20. PubMed ID: 23192919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis.
    Barbarawi M; Al-Abdouh A; Barbarawi O; Lakshman H; Al Kasasbeh M; Chen K
    Heart Fail Rev; 2022 May; 27(3):951-960. PubMed ID: 33620621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.
    Ueda P; Wintzell V; Dahlqwist E; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Melbye M; Hviid A; Svanström H; Pasternak B
    Diabetes Obes Metab; 2022 Mar; 24(3):473-485. PubMed ID: 34738703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.